Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets.


Journal

Lancet (London, England)
ISSN: 1474-547X
Titre abrégé: Lancet
Pays: England
ID NLM: 2985213R

Informations de publication

Date de publication:
16 01 2021
Historique:
received: 28 08 2020
revised: 16 10 2020
accepted: 09 11 2020
entrez: 17 1 2021
pubmed: 18 1 2021
medline: 23 2 2021
Statut: ppublish

Résumé

The accuracy of current prediction tools for ischaemic and bleeding events after an acute coronary syndrome (ACS) remains insufficient for individualised patient management strategies. We developed a machine learning-based risk stratification model to predict all-cause death, recurrent acute myocardial infarction, and major bleeding after ACS. Different machine learning models for the prediction of 1-year post-discharge all-cause death, myocardial infarction, and major bleeding (defined as Bleeding Academic Research Consortium type 3 or 5) were trained on a cohort of 19 826 adult patients with ACS (split into a training cohort [80%] and internal validation cohort [20%]) from the BleeMACS and RENAMI registries, which included patients across several continents. 25 clinical features routinely assessed at discharge were used to inform the models. The best-performing model for each study outcome (the PRAISE score) was tested in an external validation cohort of 3444 patients with ACS pooled from a randomised controlled trial and three prospective registries. Model performance was assessed according to a range of learning metrics including area under the receiver operating characteristic curve (AUC). The PRAISE score showed an AUC of 0·82 (95% CI 0·78-0·85) in the internal validation cohort and 0·92 (0·90-0·93) in the external validation cohort for 1-year all-cause death; an AUC of 0·74 (0·70-0·78) in the internal validation cohort and 0·81 (0·76-0·85) in the external validation cohort for 1-year myocardial infarction; and an AUC of 0·70 (0·66-0·75) in the internal validation cohort and 0·86 (0·82-0·89) in the external validation cohort for 1-year major bleeding. A machine learning-based approach for the identification of predictors of events after an ACS is feasible and effective. The PRAISE score showed accurate discriminative capabilities for the prediction of all-cause death, myocardial infarction, and major bleeding, and might be useful to guide clinical decision making. None.

Sections du résumé

BACKGROUND
The accuracy of current prediction tools for ischaemic and bleeding events after an acute coronary syndrome (ACS) remains insufficient for individualised patient management strategies. We developed a machine learning-based risk stratification model to predict all-cause death, recurrent acute myocardial infarction, and major bleeding after ACS.
METHODS
Different machine learning models for the prediction of 1-year post-discharge all-cause death, myocardial infarction, and major bleeding (defined as Bleeding Academic Research Consortium type 3 or 5) were trained on a cohort of 19 826 adult patients with ACS (split into a training cohort [80%] and internal validation cohort [20%]) from the BleeMACS and RENAMI registries, which included patients across several continents. 25 clinical features routinely assessed at discharge were used to inform the models. The best-performing model for each study outcome (the PRAISE score) was tested in an external validation cohort of 3444 patients with ACS pooled from a randomised controlled trial and three prospective registries. Model performance was assessed according to a range of learning metrics including area under the receiver operating characteristic curve (AUC).
FINDINGS
The PRAISE score showed an AUC of 0·82 (95% CI 0·78-0·85) in the internal validation cohort and 0·92 (0·90-0·93) in the external validation cohort for 1-year all-cause death; an AUC of 0·74 (0·70-0·78) in the internal validation cohort and 0·81 (0·76-0·85) in the external validation cohort for 1-year myocardial infarction; and an AUC of 0·70 (0·66-0·75) in the internal validation cohort and 0·86 (0·82-0·89) in the external validation cohort for 1-year major bleeding.
INTERPRETATION
A machine learning-based approach for the identification of predictors of events after an ACS is feasible and effective. The PRAISE score showed accurate discriminative capabilities for the prediction of all-cause death, myocardial infarction, and major bleeding, and might be useful to guide clinical decision making.
FUNDING
None.

Identifiants

pubmed: 33453782
pii: S0140-6736(20)32519-8
doi: 10.1016/S0140-6736(20)32519-8
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

199-207

Investigateurs

Francesco Piroli (F)
Andrea Saglietto (A)
Federico Conrotto (F)
Pierluigi Omedé (P)
Antonio Montefusco (A)
Mauro Pennone (M)
Francesco Bruno (F)
Pier Paolo Bocchino (PP)
Giacomo Boccuzzi (G)
Enrico Cerrato (E)
Ferdinando Varbella (F)
Michela Sperti (M)
Stephen B Wilton (SB)
Lazar Velicki (L)
Ioanna Xanthopoulou (I)
Angel Cequier (A)
Andres Iniguez-Romo (A)
Isabel Munoz Pousa (I)
Maria Cespon Fernandez (M)
Berenice Caneiro Queija (B)
Rafael Cobas-Paz (R)
Angel Lopez-Cuenca (A)
Alberto Garay (A)
Pedro Flores Blanco (PF)
Andrea Rognoni (A)
Giuseppe Biondi Zoccai (G)
Simone Biscaglia (S)
Ivan Nunez-Gil (I)
Toshiharu Fujii (T)
Alessandro Durante (A)
Xiantao Song (X)
Tetsuma Kawaji (T)
Dimitrios Alexopoulos (D)
Zenon Huczek (Z)
Jose Ramon Gonzalez Juanatey (JR)
Shao-Ping Nie (SP)
Masa-Aki Kawashiri (MA)
Iacopo Colonnelli (I)
Barbara Cantalupo (B)
Roberto Esposito (R)
Sergio Leonardi (S)
Walter Grosso Marra (W)
Alaide Chieffo (A)
Umberto Michelucci (U)
Dario Piga (D)
Marta Malavolta (M)
Sebastiano Gili (S)
Marco Mennuni (M)
Claudio Montalto (C)
Luigi Oltrona Visconti (L)
Yasir Arfat (Y)

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Auteurs

Fabrizio D'Ascenzo (F)

Division of Cardiology, Cardiovascular and Thoracic Department, Città della Salute e della Scienza, Turin, Italy; Cardiology, Department of Medical Sciences, University of Turin, Turin, Italy. Electronic address: fabrizio.dascenzo@gmail.com.

Ovidio De Filippo (O)

Division of Cardiology, Cardiovascular and Thoracic Department, Città della Salute e della Scienza, Turin, Italy; Cardiology, Department of Medical Sciences, University of Turin, Turin, Italy.

Guglielmo Gallone (G)

Division of Cardiology, Cardiovascular and Thoracic Department, Città della Salute e della Scienza, Turin, Italy; Cardiology, Department of Medical Sciences, University of Turin, Turin, Italy.

Gianluca Mittone (G)

Department of Computer Science, University of Turin, Turin, Italy.

Marco Agostino Deriu (MA)

Polito BIO Med Lab, Department of Mechanical and Aerospace Engineering, Politecnico di Torino, Turin, Italy.

Mario Iannaccone (M)

Department of Cardiology, S G Bosco Hospital, Turin, Italy.

Albert Ariza-Solé (A)

Department of Cardiology, University Hospital de Bellvitge, Barcelona, Spain.

Christoph Liebetrau (C)

Kerckhoff Heart and Thorax Center, Frankfurt, Germany.

Sergio Manzano-Fernández (S)

Department of Cardiology, University Hospital Virgen Arrtixaca, Murcia, Spain.

Giorgio Quadri (G)

Interventional Cardiology Unit, Degli Infermi Hospital, Turin, Italy.

Tim Kinnaird (T)

Cardiology Department, University Hospital of Wales, Cardiff, UK.

Gianluca Campo (G)

Azienda Ospedaliera Universitaria di Ferrara, Ferrara, Italy.

Jose Paulo Simao Henriques (JP)

University of Amsterdam, Academic Medical Center, Amsterdam, Netherlands.

James M Hughes (JM)

Candiolo Cancer Institute, FPO - IRCCS, Turin, Italy.

Alberto Dominguez-Rodriguez (A)

Servicio de Cardiologìa, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain.

Marco Aldinucci (M)

Department of Computer Science, University of Turin, Turin, Italy.

Umberto Morbiducci (U)

Polito BIO Med Lab, Department of Mechanical and Aerospace Engineering, Politecnico di Torino, Turin, Italy.

Giuseppe Patti (G)

Catheterization Laboratory, Maggiore della Carità Hospital, Novara, Italy.

Sergio Raposeiras-Roubin (S)

Department of Cardiology, University Hospital Álvaro Cunqueiro, Vigo, Spain.

Emad Abu-Assi (E)

Department of Cardiology, University Hospital Álvaro Cunqueiro, Vigo, Spain.

Gaetano Maria De Ferrari (GM)

Division of Cardiology, Cardiovascular and Thoracic Department, Città della Salute e della Scienza, Turin, Italy; Cardiology, Department of Medical Sciences, University of Turin, Turin, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH